A Long-Term Follow-up Study to Evaluate Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs DTX 301 (Primary)
- Indications Ornithine carbamoyltransferase deficiency disease
- Focus Adverse reactions
- Acronyms CAPtivate
- Sponsors Ultragenyx Pharmaceutical
- 10 Dec 2018 Planned End Date changed from 18 Sep 2023 to 1 Dec 2024.
- 10 Dec 2018 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.